Published in Biotech Law Weekly, August 20th, 2004
This growth corresponds with an increase in branded prescription drugs losing patent protection in coming years. As generics pose a significant threat to branded drugs, pharmaceutical companies are preparing to defend their drugs.
Sanofi has recently developed Ambien CR, a new time-released version of its blockbuster Ambien sleeping drug, according to a Pharmaceutical Business Review article. Upon successful approval, Ambien CR could reach the market by 2005, allowing Sanofi...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.